Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma

Neuro-Oncology

Volumn 12, Issue 6, 2010, Pages 528-539

  Morales, Fabiana C ^a   Molina, Jennifer R ^a   Hayashi, Yuho ^a   Georgescu, Maria Magdalena ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ezrin; FERM domain; Glioblastoma; NF2

Indexed keywords

CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; SHORT HAIRPIN RNA;

AMINO TERMINAL SEQUENCE; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; NEUROFIBROMATOSIS; PHENOTYPE; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MICE; NEUROFIBROMIN 2;

EID: 77956296330     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop060     Document Type: Article

References (43)

1. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci. 2007;64: 458-478.
2. McClatchey AI. Neurofibromatosis. Annu Rev Pathol. 2007;2: 191-216.
3. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008;131:606-615.
4. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature. 1993;363:515-521.
5. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor [erratum appears in Cell 1993;75(4):826]. Cell. 1993;72: 791-800.
6. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586-599.
7. Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 2008;8:459-468.
8. Geiger KD, Stoldt P, Schlote W, Derouiche A. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol. 2000;157:1785-1793.
9. Tynninen O, Carpen O, Jaaskelainen J, Paavonen T, Paetau A. Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol. 2004;30:472-477.
10. Turunen O, Wahlstrom T, Vaheri A. Ezrin has a COOH-terminal actinbinding site that is conserved in the ezrin protein family. J Cell Biol. 1994;126:1445-1453.
11. Cole BK, Curto M, Chan AW, McClatchey AI. Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol. 2008;28:1274-1284.
12. Li Q, Nance MR, Kulikauskas R, et al. Self-masking in an intact ERM-merlin protein: an active role for the central alpha-helical domain. J Mol Biol. 2007;365:1446-1459.
13. Pearson MA, Reczek D, Bretscher A, Karplus PA. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000;101:259-270.
14. Terawaki S, Maesaki R, Hakoshima T. Structural basis for NHERF recognition by ERM proteins. Structure. 2006;14:777-789.
15. Hamada K, Shimizu T, Matsui T, Tsukita S, Hakoshima T. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin FERM domain. EMBO J. 2000;19:4449-4462.
16. Niggli V, Andreoli C, Roy C, Mangeat P. Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. FEBS Lett. 1995;376:172-176.
17. Matsui T, Maeda M, Doi Y, et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998;140:647-657.
18. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001;1:63-72.
19. Hayashi K, Yonemura S, Matsui T, Tsukita S. Immunofluorescence detection of ezrin/radixin/moesin (ERM) proteins with their carboxylterminal threonine phosphorylated in cultured cells and tissues. J Cell Sci. 1999;112:1149-1158.
20. Morales FC, Takahashi Y, Momin S, Adams H, Chen X, Georgescu MM. NHERF1/EBP50 Head-to-tail intramolecular interaction masks association with PDZ domain ligands. Mol Cell Biol. 2007;27:2527-2537.
21. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA. 1999;96:10182-10187.
22. Nishihara H, Maeda M, Oda A, et al. DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood. 2002;100: 3968-3974.
23. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 2000;60:7033-7038.
24. Wang H,Wang H, Zhang W, Fuller GN. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002;12:95-107.
25. Reczek D, Berryman M, Bretscher A. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J Cell Biol. 1997;139:169-179.
26. Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, et al. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol. 1997;56: 735-742.
27. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer Res. 2008;68:5733-5742.
28. Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology. 2004;112:165-176.
29. Gronholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpen O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci. 1999;112:895-904.
30. Meng JJ, Lowrie DJ, Sun H, et al. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin. J Neurosci Res. 2000;62:491-502.
31. Nguyen R, Reczek D, Bretscher A. Hierarchy of merlin and ezrin N-and C-terminal domain interactions in homo-and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem. 2001;276:7621-7629.
32. Curto M, McClatchey AI. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer. 2008;98:256-262.
33. Curto M, McClatchey AI. Ezrin a metastatic detERMinant? Cancer Cell. 2004;5:113-114.
34. Hoelzinger DB, Mariani L, Weis J, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 2005;7:7-16.
35. Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res. 2004;64:2496-2501.
36. Huang L, Ichimaru E, Pestonjamasp K, et al. Merlin differs from moesin in binding to F-actin and in its intra-and intermolecular interactions. Biochem Biophys Res Commun. 1998;248:548-553.
37. Horiguchi A, Zheng R, Shen R, Nanus DM. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate. 2008;68:975-984.
38. Rustgi AK, Xu L, Pinney D, et al. Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genet Cytogenet. 1995;84:24-26.
39. Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatric Blood Cancer. 2008;50:752-756.
40. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-186.
41. Shimizu T, Seto A, Maita N, et al. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Bioll Chem. 2002;277:10332-10336.
42. Sherman L, Xu HM, Geist RT, et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene. 1997;15:2505-2509.
43. Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neuros sci. 2001;21:3360-3368.